Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial
Top Cited Papers
- 15 December 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet Gastroenterology & Hepatology
- Vol. 6 (2), 128-138
- https://doi.org/10.1016/s2468-1253(20)30330-7
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals Of Oncology, 2015
- nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III TrialJNCI Journal of the National Cancer Institute, 2014
- Pancreatic AdenocarcinomaNew England Journal of Medicine, 2014
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United StatesCancer Research, 2014
- Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trialThe Lancet Oncology, 2013
- Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicatorsCancer, 2012
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II TrialJournal of Clinical Oncology, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection PercentagesPLoS Medicine, 2010
- Preoperative Chemoradiation and Pancreaticoduodenectomy for Adenocarcinoma of the PancreasArchives of Surgery, 1992